Evidence map›Paper›PMID 38849658›Full record

ArticleActa diabetologica2024

An automated insulin delivery system from pregestational care to postpartum in women with type 1 diabetes. Preliminary experience with telemedicine in 6 patients.

Raffaella Fresa, Olimpia Bitterman, Vincenzo Cavallaro, Marianna Di Filippi, Daniela Dimarzo, Carmela Mosca, Francesca Nappi, Marilena Rispoli, Angela Napoli

Abstract read
PubMed Publisher
In one paragraph

Article in Acta diabetologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Raffaella FresaDiabetology Outpatient Clinic , Asl Salerno, District 63, Salerno, Italy.
Olimpia BittermanDiabetology Unit, San Paolo Hospital, ASL Roma 4, Civitavecchia, Rome, Italy. olimpia.bitterman@gmail.com.ORCID http://orcid.org/0000-0003-2462-3416
Vincenzo CavallaroDiabetology Outpatient Clinic , Asl Salerno, District 63, Salerno, Italy.
Marianna Di FilippiDiabetology Outpatient Clinic , Asl Salerno, District 63, Salerno, Italy.
Daniela DimarzoDiabetology Outpatient Clinic , Asl Salerno, District 63, Salerno, Italy.
Carmela MoscaDiabetology Outpatient Clinic , Asl Salerno, District 63, Salerno, Italy.
Francesca NappiDiabetology Outpatient Clinic , Asl Salerno, District 63, Salerno, Italy.
Marilena RispoliDiabetology Outpatient Clinic , Asl Salerno, District 63, Salerno, Italy.
Angela NapoliIsraelitico Hospital, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe use of most commercially available automated insulin delivery (AID) systems is off-label in pregnancy. However, an increasing number of women with type 1 diabetes (T1D) use such devices throughout pregnancy and delivery. We analysed the data of six women with T1D from a single centre (Diabetology Outpatient Clinic of District-63/Asl Salerno, Italy) who were able to start and maintain AID therapy with the MiniMed™ 780G (Medtronic, Minneapolis, MN, USA) throughout the pregestational care period, pregnancy, delivery, and postpartum.

methodsWe retrospectively collected data from six patients with T1D who received training and initiation on use of the MiniMed™ 780G and attended follow-up visits throughout pregnancy (these visits were virtual because of the COVID-19 pandemic). All patients maintained their devices in the closed-loop setting throughout pregnancy and during labour and delivery. We analysed data from the pregestational phase to the first 30 days postpartum.

resultsAll patients achieved the recommended metabolic goals before conception [median time in range (TIR) of 88% for 70-180 mg/dL; median pregnancy-specific TIR 63-140 mg/dL (ps-TIR) of 66% and maintained the ps-TIR until delivery (median ps-TIR 83%). All patients had slightly better metrics during the night than during the day, with a very low time below range of < 63 mg/dL. Optimal glycaemic values were also maintained on the day of labour and delivery (median ps-TIR 92.5%) and in the first 30 days postpartum, with no severe hypoglycaemia. The only neonatal complications were jaundice in one child and an interatrial defect in another child.

conclusionIn our well-selected and trained patients, use of the MiniMed™ 780G helped to achieve and maintain ps-metrics from the pregestational period to delivery despite the fact that the algorithm is not set to achieve the ambitious glycaemic values recommended for pregnancy.

Indexed as

Diabetes Mellitus, Type 1InsulinInsulin Infusion SystemsPostpartum PeriodPregnancy in DiabeticsTelemedicineAdultBlood GlucoseCOVID-19FemaleHumansHypoglycemic AgentsItalyPregnancyRetrospective StudiesBlood GlucoseHypoglycemic AgentsInsulinInsulin pumpPregnancyTelemedicineType 1 diabetes

Identifiers

PMID38849658

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.